A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
NCT07903415
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called PF-08098488) in people with advanced solid tumors (cancer that cannot be removed with surgery or has spread to other parts of the body). PF-08098488 is being studied as a possible treatment for certain types of cancer. These include non-small cell lung cancer, pancreatic cancer, stomach or gastroesophageal junction cancer, and esophageal cancer. This study will also help researchers learn how the study medicine moves through and affects the body.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Pancreatic Ductal Adenocarcinoma
- Esophageal Cancer
- Carcinoma, Non-Small-Cell Lung (NSCLC)
- Gastric Carcinoma
- Gastroesophageal Junction Adenocarcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Pfizer
- Last updated on ClinicalTrials.gov
- October 29, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Michigan · 1
- START Midwest, LLC · Grand Rapids, MI
Texas · 1
- START San Antonio, LLC · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.